|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Mannual7th. Springer;
New York, NY: 2010
|
|
3
|
Dukes CE and Bussey HJ: The spread of
rectal cancer and its effect on prognosis. Br J Surg. 12:309–320.
1958.
|
|
4
|
Hermanek P: TNM Supplement 1993: A
commentary on uniform Use. Berlin. Springer–Verlag. 1993.
|
|
5
|
Shirouzu K, Akagi Y, Fujita S, Ueno H,
Takii Y, Komori K, Ito M and Sugihara K: Japanese Society for
Cancer of the Colon and Rectum (JSCCR) on clinical significance of
the mesorectal extension of rectal cancer: Clinical significance of
the mesorectal extension of rectal cancer: A japanese
multi-institutional study. Ann Surg. 253:704–710. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shin R, Jeong SY, Yoo HY, Park KJ, Heo SC,
Kang GH, Kim WH and Park JG: Depth of mesorectal extension has
prognostic significance in patients with T3 rectal cancer. Dis
Colon Rectum. 55:1220–1228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sueda T, Ohue M, Noura S, Shingai T,
Nakanishi K and Yano M: Prognostic significance of a preoperative
magnetic resonance imaging assessment of the distance of mesorectal
extension in clinical T3 lower rectal cancer. Surg Today.
46:1249–1257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith NJ, Bees N, Barbachano Y, Norma AR,
Swift RI and Brown G: Preoperative computed tomography staging of
nonmetastatic colon cancer predicts outcome: Implications for
clinical trials. Br J Cancer. 96:1030–1036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zinicola R, Pedrazzi G, Haboubi N and
Nicholls RJ: The degree of extramural spread of T3 rectal cancer:
An appeal to the American joint committee on cancer. Colorectal
Dis. 19:8–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wittekind C: TNM supplement: A commentary
on uniform use. 3rd edition. Hoboken. Wiley–Liss. 2003.
|
|
11
|
Sobin LH, Gospodarowicz MK and Wittekind
C: UICC TNM Classification of Malignant Tumors7th. Wiley-Blackwell;
New York, NY: 2009
|
|
12
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese society for cancer of the colon and rectum (JSCCR)
guidelines 2014 for the treatment of colorectal cancer. Int J Clin
Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumar A, Knnecke HF, Renouf DJ, Lim HJ,
Gill S, Woods R, Speers C and Cheung WY: Adjuvant chemotherapy use
and outcomes of patients with high-risk versus low-risk stage II
colon cancer. Cancer. 121:527–534. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshitani S and Takashima S: Efficacy of
postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly
patients with resected colorectal cancer. Cancer Biother
Radiopharm. 24:35–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Foxtrot Collaborative Group, : Feasibility
of preoperative chemotherapy for locally advanced, operable colon
cancer: The pilot phase of a randomised controlled trial. Lancet
Oncol. 13:1152–1160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Merkel S, Mansmann U, Siassi M,
Papadopoulos T, Hohenberger W and Hermanek P: The prognostic
inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis.
16:298–304. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bertelsen CA, Neuenschwander AU, Jansen
JE, Wihelmsen M, Kirkegaard-Klitbo A, Tenma JR, Bols B, Ingeholm P,
Rasmussen LA, Jepsen LV, et al: Disease-free survival after
complete mesocolic excision compared with conventional colon cancer
surgery: A retrospective, population-based study. Lancet Oncol.
16:161–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taieb J, Tabernero J, Mini E, Subit F,
Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN,
Blons H, et al: Oxaliplatin, fluorouracil, and leucovorin with or
without cetuximab in patients with resected stage III colon cancer
(PETACC-8): An open-label, randomized phase 3 trial. Lancet Oncol.
15:862–873. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Colvin H, Mizushima T, Eguchi H, Takiguchi
S, Doki Y and Mori M: Gastroenterological surgery in Japan: The
past, the present and the future. Ann Gastroenterol Surg. 1:5–10.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matsuda T, Yamashita K, Hasegawa H,
Oshikiri T, Hosono M, Higashino N, Yamamoto M, Matsuda Y, Kanaji S,
Nakamura T, et al: Recent updates in the surgical treatment of
colorectal cancer. Ann Gastroenterol Surg. 2:129–136. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Finlay IG, Meek D, Brunton F and McArdle
CS: Growth rate of hepatic metastases in colorectal carcinoma. Br J
Surg. 75:641–644. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tanaka K, Shimada H, Miura M, Fujii Y,
Yamaguchi S, Endo I, Sekido H, Togo S and Ike H: Metastatic tumor
doubling time: Most important prehepatectomy predictor of survival
and non-recurrence of hepatic colorectal cancer metastasis. World J
Surg. 28:263–270. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeamari S, Roos E and Stewart FA: Tumour
seeding in peritoneal wound sites in relation to growth-factor
expression in early granulation tissue. Eur J Cancer. 40:1431–1440.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fahmy RG, Dass CR, Sun LQ, Chesterman CN
and Khachigian LM: Transcription factor Egr-1 supports
FGF-dependent angiogenesis during neovascularization and tumor
growth. Nat Med. 9:1026–1032. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schelfhout VR, Coene ED, Delaey B,
Waeytens AA, De Rycke L, Deleu M and De Potter CR: The role of
heregulin-alpha as a motility factor and amphiregulin as a growth
factor in wound healing. J Pathol. 198:523–533. 2002. View Article : Google Scholar : PubMed/NCBI
|
